Search
Ascendis Pharma A/S
ASNDAdd to Watchlist
261.580USD
+23.570+9.90%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
16.25BMarket Cap
37.69P/E TTM
More Details of Ascendis Pharma A/S Company
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Ascendis Pharma A/S Info
Ticker SymbolASND
Company nameAscendis Pharma A/S
IPO dateJan 28, 2015
CEOMoller Mikkelsen (Jan)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endJan 28
AddressTuborg Boulevard 12
CityHELLERUP
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryDenmark
Postal code2900
Phone4570222244
Websitehttps://ascendispharma.dk/
Ticker SymbolASND
IPO dateJan 28, 2015
CEOMoller Mikkelsen (Jan)
Company Executives of Ascendis Pharma A/S
Name
Name/Position
Position
Shareholding
Change
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+66.49%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.66K
+40.20%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
--
-100.00%
Dr. Stina Singel, M.D., Ph.D.
Dr. Stina Singel, M.D., Ph.D.
Executive Vice President, Head of Clinical Development, Oncology
Executive Vice President, Head of Clinical Development, Oncology
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
Mr. Mads Bodenhoff
Mr. Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer
Senior Vice President, Head of Finance and Principal Accounting Officer
--
-100.00%
Dr. Aimee Shu,, M.D.
Dr. Aimee Shu,, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+66.49%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.66K
+40.20%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
--
-100.00%
FAQs
Who are the top five shareholders of Ascendis Pharma A/S?
The top five shareholders of Ascendis Pharma A/S are: Mr. Flemming Steen Jensen
How many institutions hold shares of Ascendis Pharma A/S (ASND)?
As of 2026Q1, 582 institutions hold shares of Ascendis Pharma A/S, with a combined market value of approximately 69.20M, accounting for 111.42% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1676383.00.
What is the biggest source of revenue for Ascendis Pharma A/S?
In 2026Q1, the Commercial sale of products business generated the highest revenue for Ascendis Pharma A/S, amounting to 683.57M and accounting for 94.92% of total revenue.
